Aquestive Therapeutics, Inc. $AQST Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 87.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,845 shares of the company’s stock after selling 173,143 shares during the quarter. Sei Investments Co.’s holdings in Aquestive Therapeutics were worth $103,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of AQST. Vanguard Group Inc. increased its stake in Aquestive Therapeutics by 30.8% during the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock valued at $31,651,000 after buying an additional 1,333,627 shares during the period. Federated Hermes Inc. lifted its stake in shares of Aquestive Therapeutics by 159.4% in the 4th quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock worth $13,132,000 after acquiring an additional 1,249,044 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Aquestive Therapeutics by 6,233.4% in the 4th quarter. BNP Paribas Financial Markets now owns 1,171,675 shares of the company’s stock worth $7,569,000 after acquiring an additional 1,153,175 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Aquestive Therapeutics by 804.6% in the fourth quarter. Wells Fargo & Company MN now owns 1,188,531 shares of the company’s stock valued at $7,678,000 after acquiring an additional 1,057,145 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Aquestive Therapeutics by 53.7% in the fourth quarter. State Street Corp now owns 2,462,778 shares of the company’s stock valued at $15,910,000 after acquiring an additional 860,562 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Trading Up 0.7%

NASDAQ:AQST opened at $4.32 on Wednesday. The company has a 50-day moving average of $4.15 and a 200-day moving average of $4.10. The firm has a market cap of $542.20 million, a price-to-earnings ratio of -6.65 and a beta of 1.49. Aquestive Therapeutics, Inc. has a twelve month low of $2.93 and a twelve month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. On average, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.45 earnings per share for the current year.

Analyst Ratings Changes

AQST has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Oppenheimer initiated coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $8.50.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the transaction, the director owned 25,000 shares of the company’s stock, valued at approximately $125,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.81% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.